Sandoz presented its net-sales performance for the first quarter of 2026, noting that performance is in line with company ...

Both Alvotech ALVO and Teva Pharmaceuticals TEVA operate in the biosimilar space, but their business models differ significantly. ALVO has built its revenue model around partnerships, relying on ...

AMRX targets 2027 upside through biosimilars scale, new complex launches, and Specialty recovery after 2026 Rytary erosion ...

The Association for Accessible Medicines and its Biosimilars Council have released an analysis undertaken by the IQVIA Institute for Human Data Science on behalf of AAM assessing the impact of patent ...

Add Yahoo as a preferred source to see more of our stories on Google. Draft guidance from the FDA would allow companies to scale back on the studies and trials needed to prove that a biosimilar ...

Amneal Pharmaceuticals AMRX is leaning into a playbook that can work in multiple market backdrops. The company is pairing ...

A 10-year push for more biosimilars in the U.S. has led to a surge in copycat entrants, bringing more attention to the legal ...

US pharmaceutical regulators with the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) say they plan to release two new guidance documents on, separately, the ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...

New legislation would authorize pharmacists to substitute a biosimilar when filling a prescription, just like a generic, provided your doctor agrees.

The Association for Accessible Medicines (AAM), AARP, Kaiser Permanente and more than a dozen other groups are raising concerns with the recently renegotiated version of the North American Free Trade ...

Anna Wolters-Höhne of Bird & Bird summarises proposed updates regarding market access activities and explains the practical ...